Response to Combined Antiretroviral Therapy According to Gender and Origin in a Cohort of Naive HIV-Infected Patients: GESIDA-5808 Study

dc.contributor.authorPérez-Molina, José A.spa
dc.contributor.authorMora Rillo, Martaspa
dc.contributor.authorSuárez-Lozano, Ignaciospa
dc.contributor.authorCasado Osorio, José L.spa
dc.contributor.authorTeira Cobo, Ramónspa
dc.contributor.authorRivas González, Pablospa
dc.contributor.authorPedrol Clotet, Enricspa
dc.contributor.authorHernando Jeréz, María Asunción
dc.contributor.authorDomingo Pedrol, Perespa
dc.contributor.authorBarquilla Díaz, Elenaspa
dc.contributor.authorEsteban, Herminiaspa
dc.contributor.authorGonzález-García, Juanspa
dc.date.accessioned2013-11-27T17:26:52Z
dc.date.available2013-11-27T17:26:52Z
dc.date.issued2012spa
dc.description.abstractWe analyzed differences in response to combined antiretroviral therapy (cART) according to sex and geographic origin in a retrospective comparative study of Spanish-born and immigrant patients initiating cART. The primary endpoint was time to treatment failure (TTF), defined as virological failure, death, opportunistic infection, interruption of cART, or loss to follow-up. Late diagnosis was defined as a CD4+ cell count ≤ 200 cells/mm3 and/or AIDS at initiation of cART. Survival was analyzed using Kaplan-Meier analysis and Cox regression. We followed 1,090 patients, of whom 318 were women (45.6% immigrant women [IW]). At initiation of treatment, women had a higher CD4+ count than men (217 vs 190 cells/mm3), a lower viral load (4.7 vs 5 log), and fewer were late starters (49% vs 59%). The adjusted risk of TTF between women and men was not significantly different (hazard ratio [HR], 1.10; 95% CI, 0.79-1.53). TTF was shorter among IW than Spanish-born women (124 weeks [95% CI, 64-183] vs 151 [95% CI, 127-174]) and loss to follow-up was double that of Spanish-born women (25.5% vs 11.6%). Although response to cART was similar for both sexes, men started treatment later. IW were more frequently lost to follow-up and switched treatment. Measures to improve medical follow-up after initiation of cART should be promoted among this minority group. Response to Combined Antiretroviral Therapy According to Gender and Origin in a Cohort of Naïve HIV-Infected Patients: GESIDA-5808 Study. Available from: https://www.researchgate.net/publication/224971412_Response_to_Combined_Antiretroviral_Therapy_According_to_Gender_and_Origin_in_a_Cohort_of_Naive_HIV-Infected_Patients_GESIDA-5808_Study.spa
dc.description.impact2.304 JCR (2012) Q2, 122/261 Pharmacology & pharmacy; Q3, 42/70 Infectious diseasesspa
dc.identifier.citationPérez-Molina, J. A., Mora-Rillo, M., Suárez-Lozano, I., Casado-Osorio, J. L., Teira-Cobo, R., Rivas-González, P., ..., & González-García, J. (2012). Response to combined antiretroviral therapy according to gender and origin in a cohort of naive HIV-infected patients: GESIDA-5808 study. HIV Clinical Trials, 13(3), 131-141.spa
dc.identifier.doi10.1310/hct1303-131spa
dc.identifier.issn15284336spa
dc.identifier.urihttp://hdl.handle.net/11268/1115
dc.language.isoengspa
dc.peerreviewedSispa
dc.rights.accessRightsrestricted accessen
dc.subject.otherCartspa
dc.subject.otherHiv Infectionspa
dc.subject.otherImmigrantsspa
dc.subject.otherNaivespa
dc.subject.otherAfrican Immigrant Womenspa
dc.subject.otherSex-Differencesspa
dc.subject.otherProgressionspa
dc.subject.otherPregnancyspa
dc.subject.otherHiv/Aidsspa
dc.subject.otherDeathspa
dc.subject.otherPharmacokineticsspa
dc.subject.otherSeroconversionspa
dc.subject.otherParticipantsspa
dc.subject.otherInfectious Diseasesspa
dc.subject.otherPharmacology & Pharmacyspa
dc.subject.unescoSidaspa
dc.titleResponse to Combined Antiretroviral Therapy According to Gender and Origin in a Cohort of Naive HIV-Infected Patients: GESIDA-5808 Studyspa
dc.typejournal articlespa
dspace.entity.typePublication
relation.isAuthorOfPublicationc5d9ddbc-f605-406e-8dc1-8386b2e030cd
relation.isAuthorOfPublication.latestForDiscoveryc5d9ddbc-f605-406e-8dc1-8386b2e030cd

Files